Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2018 Nov;40(1):213-218.
doi: 10.1080/0886022X.2018.1455591.

Characteristics of patients with coexisting IgA nephropathy and membranous nephropathy

Pei Chen  1   2   3   4 , Su-Fang Shi  1   2   3   4 , Zhen Qu  1   2   3   4 , Na Zhao  1   2   3   4 , Xin-Fang Xie  1   2   3   4 , Ji-Cheng Lv  1   2   3   4 , Li-Jun Liu  1   2   3   4 , Hong Zhang  1   2   3   4
Affiliations
Comparative Study

Characteristics of patients with coexisting IgA nephropathy and membranous nephropathy

Pei Chen et al. Ren Fail. 2018 Nov.

Abstract

Background: Coexistence of IgA nephropathy (IgAN) and membranous nephropathy (MN) in the same patient is rare. Few studies have reported the clinical and pathological features of patients with combined IgAN and MN (IgAN-MN).

Methods: The clinico-pathological features, levels of galactose-deficient IgA1 (Gd-IgA1) and autoantibodies against M-type transmembrane phospholipase A2 receptor (anti-PLA2R) in sera were compared among IgAN-MN, IgAN, and MN patients.

Results: Twenty-six patients with biopsy-proven IgAN-MN were enrolled. The mean age at biopsy was 43.6 ± 15.9 years, and 65.4% were male. Proteinuria and estimated glomerular filtration rate (eGFR) levels in patients with IgAN-MN were similar to that of MN patients. Compared with the IgAN patients, IgAN-MN patients showed a higher median proteinuria level (4.3 vs. 1.2 g/day, p < .001), and a higher mean eGFR level (101.8 ± 25.4 vs. 78.6 ± 26.9 mL/min/1.73 m2, p < .001). IgAN-MN patients presented with milder pathological lesions than IgAN patients according to the Oxford Classification. IgAN-MN patients had comparable serum levels of Gd-IgA1 with those of IgAN patients (353.4 ± 95.5 vs. 347.0 ± 109.6 U/mL, p = .801). Percentage of IgAN-MN patients with detectable serum levels of anti-PLA2R was lower than that of MN patients (38.5% vs. 68.6%, p = .011).

Conclusions: IgAN-MN patients display similar clinical features to MN patients and milder pathological lesions than IgAN patients. IgAN-MN patients have similar levels of Gd-IgA1 to those of IgAN patients, and a lower proportion of anti-PLA2R than MN patients.

Keywords: Anti-PLA2R; Gd-IgA1; IgA nephropathy; IgAN–MN; membranous nephropathy.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Flowchart of patient selection.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Levy M, Berger J.. Worldwide perspective of IgA nephropathy. Am J Kidney Dis. 1988;12:340–347. - PubMed
    1. Coppo R, Troyanov S, Bellur S, et al. . Validation of the Oxford Classification of IgA nephropathy in cohorts with different presentations and treatments. Kidney Int. 2014;86:828–836. - PMC - PubMed
    1. Barratt J, Feehally J, Smith AC.. Pathogenesis of IgA nephropathy. Semin Nephrol. 2004;24:197–217. - PubMed
    1. Suzuki K, Honda K, Tanabe K, et al. . Incidence of latent mesangial IgA deposition in renal allograft donors in Japan. Kidney Int. 2003;63:2286–2294. - PubMed
    1. Suzuki H, Moldoveanu Z, Hall S, et al. . IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1. J Clin Invest. 2008;118:629–639. - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources